Spiro-Compound Polymorphs for Selective M1 Muscarinic Agonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds targeting the M1 muscarinic receptor for treating Alzheimer's disease and other neurodegenerative conditions face challenges due to adverse cholinergic effects and lack of selectivity, necessitating the development of safer and more selective modulators.
Innovation Solution
The development of novel crystalline polymorphs of (S)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro[4.5]decane-3-one, specifically Forms I, II, and III, which are stable, pharmaceutically acceptable forms that selectively stimulate the M1 muscarinic receptor with reduced adverse effects, suitable for pharmaceutical manufacturing and clinical use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If xanomeline and other related muscarinic agonists are used to treat Alzheimer's disease, then improvements in behavioral disturbances are achieved, but unacceptable safety margin with respect to cholinergic adverse events occurs
Solution Approach 1:
The patent applies local quality by developing compounds with subtype-specific selectivity. The spiro-compound of Formula (I) is designed to selectively target M1 muscarinic receptors while sparing other subtypes (M2-M5), thereby achieving therapeutic effects in Alzheimer's disease without the broad cholinergic adverse events associated with non-selective agonists like xanomeline.
Solution Approach 2:
The patent employs parameter changes by optimizing the molecular structure through specific substituents (R1-R6 groups) to modulate receptor selectivity. By varying these structural parameters, the compound achieves enhanced M1 selectivity profile, transforming the safety profile from unacceptable (with xanomeline) to tolerable while maintaining efficacy.
2Reliability
If compounds with improved M1 selectivity are developed, then selectivity for M1 receptor is enhanced, but manufacturing complexity and regulatory compliance challenges arise
Solution Approach 1:
The patent applies segmentation by dividing the complex spiro-compound synthesis into modular steps with well-defined intermediates. The synthetic route includes distinct stages for forming the spiro core, introducing substituents R1-R6, and purifying the final product, making the manufacturing process more manageable and compliant with cGMP regulations.
Solution Approach 2:
The patent uses parameter changes by optimizing crystalline form selection (polymorphs) to improve manufacturing properties. The specific crystalline forms disclosed offer improved stability, solubility, and processability, facilitating cGMP-compliant manufacturing while maintaining the desired M1 selectivity profile.
3Adaptability or versatility
If non-selective muscarinic agonists are used, then broader receptor coverage is achieved, but adverse effects from stimulation of other muscarinic receptors occur
Solution Approach 1:
The patent applies local quality by designing the spiro-compound with specific structural features that confer M1 subtype selectivity. The R1-R6 substituents are strategically positioned to interact with M1-specific binding pocket residues, enabling selective M1 activation without significant engagement of M2-M5 receptors, thus avoiding their associated adverse effects.
Solution Approach 2:
The patent converts the potential harm of broad receptor coverage into benefit by using structure-selective design. Instead of accepting non-selective activation that causes adverse events, the compound is engineered to exploit the unique structural features of the M1 receptor, transforming the challenge of selectivity into a therapeutic advantage.
Data Source
AI summary
Provided are novel crystalline forms of a spiro-compound which acts as a muscarinic acetylcholine receptor agonist. In particular, isolated crystalline polymorphs of (S)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro[4.5]decane-3-one are described which have favorable properties in pharmaceutical manufacture. Also provided are methods to prepare said crystalline polymorphs, and to convert them into each other as well as methods for preparing medicaments containing the same which are suitable for use in the treatment of diseases and disorders that respond to modulation of the muscarinic acetylcholine receptor.